Sunday, December 12, 2021 8:13:41 AM
All about India’s first needle-free COVID-19 vaccine 12/3/21
Covaxin was India’s first indigenous vaccine against COVID-19 and now we have the second indigenous jab which will soon be available across seven Indian states. What makes ZyCoV-D vaccine unique is that it is a needle-less jab which had earned authorization from the Drugs Controller General of India in August.
It will also be eligible for 12-19 years
Right now the vaccine will only be administered to adults until it’s able to strengthen its production capacity. That’s when it will be extended to adolescents too, as per Dr Sandeep Patil, Chief Intensivist, Fortis Hospital, Kalyan.
ZyCoV-D: India’s first needle-less vaccine
ZyCoV-D will be a needle-less vaccine which will be administered using a needle-free applicator instead of traditional syringes. It is a three-dose vaccine, whose second and third doses are to be taken 28 and 56 days after the first. As per reports, the single dose of the vaccine will be made available to the Centre at Rs 376 including the cost of the jet applicator and GST, taking the price of 3-dose jab to Rs 1,128.
The Zydus Cadila shot will not yet be a part of the national vaccination drive but will be available in seven states first, a top government official shared.
ZyCoV-D is a DNA-plasmid vaccine
This is the first COVID-19 vaccine candidate developed on a plasmid DNA platform to be commercially introduced anywhere in the world. To understand what’s DNA-PLASMID vaccine, we need to understand that most vaccines are made using a weakened or killed form of the infectious agent. In this case, a piece of DNA containing the genes for the antigens is used to inject in the body. This helps the body to learn how to respond against the antigen. So when the pathogen attacks, the body can then generate specific antibodies to combat COVID.
It has shown 66.66% efficacy in phase 3 trial
This was the first vaccine which was also tested in the adolescent population (12-18 years). The vaccine has been jointly developed in partnership with the Department of Biotechnology, showing a primary efficacy of 66.66% in phase 3 clinical trials. Putting aside storage concerns, the vaccine remains stable in room temperatures for three months, unlike mRNA vaccines which require ultra-cold storage systems.
Efficacy
Dr Sandeep Patil, Chief Intensivist, Fortis Hospital, Kalyan, shares that according to the data collected during this trial, this vaccine had already exhibited robust immunogenicity, tolerability and safety profile in the adaptive Phase I/II clinical trials carried out earlier. It said this vaccine works against the Delta variant as the trials have been carried out in more than 50 clinical sites spread across the country, and during the peak of the second wave of COVID19, have shown the vaccine’s efficacy against the new mutant strains, especially the Delta variant. Data also shows equivalent immunogenicity with that of the three-dose regimen. Therefore, a two-dose regimen approval is also expected. However, the expert panel will review more data on the same.
How safe are genetic vaccines?
Genetic vaccines are considered safe for usage as they are not produced using live components of the virus, so there is no risk of infection. For manufacturing such vaccines genetic information of the actual virus is used.
Besides Zydus Cadila several other pharmaceutical giants across the globe are exploring DNA vaccines. Japanese biotechnology company AnGes and the US-based Inovio are some prominent names.
https://news.google.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?hl=en-US&gl=US&ceid=US%3Aen
Recent INO News
- INOVIO Reports Inducement Grants Under Inducement Plan • PR Newswire (US) • 05/01/2024 12:00:00 PM
- INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024 • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO to Participate in Upcoming Investor Conferences in May • PR Newswire (US) • 04/29/2024 12:00:00 PM
- INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants • PR Newswire (US) • 04/15/2024 10:39:00 PM
- INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine • PR Newswire (US) • 03/26/2024 10:28:00 PM
- INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting • PR Newswire (US) • 03/06/2024 12:00:00 PM
- U.S. Stock Futures Gain Ahead of Economic Insights; Oil Prices Climb • IH Market News • 03/06/2024 11:02:03 AM
- INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024 • PR Newswire (US) • 02/21/2024 01:00:00 PM
- INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference • PR Newswire (US) • 02/07/2024 04:46:00 PM
- INOVIO Reports Inducement Grant Under Inducement Plan • PR Newswire (US) • 02/02/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/01/2024 05:15:24 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:01:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:02:31 PM
- INOVIO Announces Effective Date of 1-for-12 Reverse Stock Split • PR Newswire (US) • 01/23/2024 01:00:00 PM
- INOVIO to Participate in Virtual Fireside Chat on the Potential Treatment of Recurrent Respiratory Papillomatosis with Key Opinion Leader • PR Newswire (US) • 01/22/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2024 10:27:59 PM
- INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI™ (toripalimab-tpzi) • PR Newswire (US) • 01/04/2024 01:00:00 PM
- INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program • PR Newswire (US) • 01/03/2024 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2023 09:05:57 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/17/2023 09:00:28 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:35:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:59 PM
- INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights • PR Newswire (US) • 11/09/2023 09:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:00:10 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM